Compare LPLA & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LPLA | DGX |
|---|---|---|
| Founded | 1989 | 1967 |
| Country | United States | United States |
| Employees | 10000 | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8B | 23.1B |
| IPO Year | 2010 | 1996 |
| Metric | LPLA | DGX |
|---|---|---|
| Price | $295.48 | $195.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $422.08 | $208.62 |
| AVG Volume (30 Days) | ★ 900.5K | 637.3K |
| Earning Date | 05-07-2026 | 04-21-2026 |
| Dividend Yield | 0.40% | ★ 1.76% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | ★ 10.92 | 8.75 |
| Revenue | ★ $16,989,479,000.00 | $11,035,000,000.00 |
| Revenue This Year | $29.59 | $7.53 |
| Revenue Next Year | $13.38 | $3.77 |
| P/E Ratio | $27.15 | ★ $22.34 |
| Revenue Growth | ★ 37.18 | 11.78 |
| 52 Week Low | $262.83 | $157.20 |
| 52 Week High | $402.98 | $213.50 |
| Indicator | LPLA | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 42.19 |
| Support Level | $282.27 | $194.77 |
| Resistance Level | $380.68 | $197.55 |
| Average True Range (ATR) | 9.90 | 4.18 |
| MACD | 2.67 | -0.81 |
| Stochastic Oscillator | 37.84 | 18.14 |
LPL Financial is the largest US independent broker-dealer, with more than 32,000 financial advisors affiliated with its platform and roughly 11 million customer accounts at the end of 2025. The firm earns the bulk of its profit from interest income earned on client cash balances and from advisory fees and commissions tied to the $2.4 trillion in assets under management or advisory on its platform at year-end 2025. LPL specializes in the provision of turnkey wealth management services for affiliated independent advisors, but maintains a diverse array of affiliation modalities, running the gamut from more traditional employee models to a pure RIA custody approach. It earns tuck-in revenue from recordkeeping fees and the provision of software tools and services to its advisor base.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.